Patent intelligence · CA
CA 2439319
PROCEDE DE PREPARATION DE (E)-5-(2-BROMOVINYL)-2'-DESOXYURIDINE
PROCEDE DE PREPARATION DE (E)-5-(2-BROMOVINYL)-2'-DESOXYURIDINE
Patent details — CA 2439319
- Jurisdiction
- CA
- Status
- expired
- Grant date
- Sep 6, 2002
- Expiration
- Sep 1, 2022
- Applicant
- MENARINI RICERCHE SPA [IT]
- CPC classes
- A61P/3112, A61P/3122
Quick answer
CA 2439319 (PROCEDE DE PREPARATION DE (E)-5-(2-BROMOVINYL)-2'-DESOXYURIDINE) is held by MENARINI RICERCHE SPA [IT]. Status: expired. Granted Sep 6, 2002. Expires Sep 1, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MENARINI RICERCHE SPA [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/3112, A61P/3122
More from MENARINI RICERCHE SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2024252263
COMPOSITIONS SOLIDES DE DICHLORHYDRATE D'ÉLACESTRANT, LEURS PROCÉDÉS DE FABRICATION ET MÉTHODES DE TRAITEMENT LES UTILISANT
granted -
WO 2024023766
POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K
granted -
CA 3259243
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2
granted -
CA 3259252
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3
granted -
WO 2022029639
FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K
granted -
US 2021015826
ANTICANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
granted -
US 2020040086
PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
granted -
CA 3102476
ASSOCIATIONS PHARMACEUTIQUES
granted
Frequently asked questions
What is US patent 2439319?
CA 2439319 (PROCEDE DE PREPARATION DE (E)-5-(2-BROMOVINYL)-2'-DESOXYURIDINE) is held by MENARINI RICERCHE SPA [IT]. Status: expired. Granted Sep 6, 2002. Expires Sep 1, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2439319?
MENARINI RICERCHE SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 2439319 expire?
Our index shows an expiration date of Sep 1, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.